propranolol and Peritonitis studies

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Peritonitis: INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.

Research Excerpts

Excerpt	Relevance	Reference
"It has been suggested that propranolol may have a protective effect on the development of spontaneous bacterial peritonitis by increasing the motility of the bowel and lowering the pressure of the portal vein."	7.73	Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? ( Archimandritis, AJ; Burroughs, AK; Cholongitas, E; Manesis, EK; Papatheodoridis, GV, 2006)
"Sclerosing peritonitis developed in a 56-year-old white man who had been receiving propranolol (320 mg/day) for hypertension and angina pectoris since December 1976."	7.66	Sclerosing peritonitis and propranolol. ( Ahmad, S, 1981)
"Sclerosing peritonitis developed in a 43-year-old man with angina pectoris who had been receiving the beta-adrenergic receptor antagonist, propranolol."	7.66	Sclerosing peritonitis and propranolol. ( Harty, RF, 1978)
"We assessed the impact of propranolol on death, risk of hepatorenal syndrome and peritonitis in patients with cirrhosis."	3.83	Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. ( Bang, UC; Bendtsen, F; Benfield, T; Hyldstrup, L; Jensen, JE, 2016)
"It has been suggested that propranolol may have a protective effect on the development of spontaneous bacterial peritonitis by increasing the motility of the bowel and lowering the pressure of the portal vein."	3.73	Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? ( Archimandritis, AJ; Burroughs, AK; Cholongitas, E; Manesis, EK; Papatheodoridis, GV, 2006)
"Sclerosing peritonitis developed in a 56-year-old white man who had been receiving propranolol (320 mg/day) for hypertension and angina pectoris since December 1976."	3.66	Sclerosing peritonitis and propranolol. ( Ahmad, S, 1981)
"Sclerosing peritonitis developed in a 43-year-old man with angina pectoris who had been receiving the beta-adrenergic receptor antagonist, propranolol."	3.66	Sclerosing peritonitis and propranolol. ( Harty, RF, 1978)
"We studied the effects of alcohol and propranolol on the course of peritonitis in rabbits."	3.66	Propranolol antagonizes the anti-inflammatory effect of alcohol and improves survival of infected intoxicated rabbits. ( Buckley, RM; MacGregor, RR; Ventura, ES, 1978)
"Bacterial infections have been hypothetized to be a trigger of variceal bleeding in cirrhotic patients and beta-blockers may have a protective effect by decreasing bacterial translocation, reducing portal pressure."	2.45	beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. ( Burra, P; Burroughs, AK; Cholongitas, E; Leandro, G; Patch, D; Senzolo, M; Thalheimer, U, 2009)

Research

Studies (27)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Change in Serum Creatinine From Baseline

Incidence of Treatment Failure

Timeframe	Studies, this research(%)	All Research%
pre-1990	15 (55.56)	18.7374
1990's	1 (3.70)	18.2507
2000's	7 (25.93)	29.6817
2010's	4 (14.81)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Bang, UC	1
Benfield, T	1
Hyldstrup, L	1
Jensen, JE	1
Bendtsen, F	1
Senzolo, M	3
Cholongitas, E	3
Burra, P	1
Leandro, G	1
Thalheimer, U	1
Patch, D	1
Burroughs, AK	4
Kalra, S	1
Atia, A	1
McKinney, J	1
Borthwick, TR	1
Smalligan, RD	1
Fries, W	1
Buda, A	1
Pizzuti, D	1
Nadal, E	2
Sturniolo, GC	1
D'Incà, R	1
Wong, F	1
Salerno, F	1
Angeli, P	1
Abraldes, JG	1
Tarantino, I	1
Turnes, J	1
Garcia-Pagan, JC	1
Rodés, J	1
Bosch, J	1
Soylu, AR	1
Dökmeci, G	1
Tezel, A	1
Amuca, H	1
Umit, H	1
Papatheodoridis, GV	1
Manesis, EK	1
Archimandritis, AJ	1
Youn, KH	1
Kim, DJ	1
Landman, MD	1
Longmire, WP	1
Nicholls, JT	1
Rutty, DA	1
Ing, TS	1
Daugirdas, JT	1
Gandhi, VC	1
Marigold, JH	1
Pounder, RE	1
Pemberton, J	1
Thompson, RP	2
Ahmad, S	1
Frishman, W	1
Silverman, R	1
Strom, J	1
Elkayam, U	1
Sonnenblick, E	1
Harty, RF	1
Buckley, RM	1
Ventura, ES	1
MacGregor, RR	1
Benny, PS	1
Denham, HE	1
Panting, AL	1
Jackson, BT	1
Gurry, JF	1
Cunningham, IG	1
Brooke, BN	1
Riabrsev, VG	1
Iarema, IV	1
Dzheĭranov, FD	1
Mezvrishvili, GO	1
Fil'chev, MI	1
Sjöqvist, A	1
Hallerbäck, B	1
Glise, H	1
Chepkiĭ, LP	1
Pys'ko, SA	1
Shemchuk, AS	1
Kandel, G	1
Diamant, NE	1
Holzer, P	1
Lippe, IT	1
Holzer-Petsche, U	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study[NCT02123576]		12 participants (Actual)	Interventional	2014-04-30	Terminated (stopped due to Poor enrollment of study population)
Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy[NCT01851252]	Phase 1	19 participants (Actual)	Interventional	2013-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	g/dL (Mean)
Treatment	0.48
Placebo	0.03

Defined as creatinine level above baseline value after day 7, dialysis or death (NCT02123576)
Timeframe: up to day 14

Number of Participants With Combined Outcome of Treatment Success and Partial Response

Intervention	Participants (Count of Participants)
Treatment	3
Placebo	3

We define as serum creatinine level decreased by >50% from baseline but not to <1.5 mg/dL, without dialysis or HRS recurrence (NCT02123576)
Timeframe: 14 days

Number of Participants With Treatment Success

Intervention	Participants (Count of Participants)
Treatment	1
Placebo	2

We define this as a decrease in serum creatinine level to <1.5 mg/dL without dialysis or death (NCT02123576)
Timeframe: 14 days

Overall Survival

Intervention	Participants (Count of Participants)
Treatment	1
Placebo	1

This will be the combination of transplant free survival and those patients who received liver transplant (NCT02123576)
Timeframe: up to 1 year

Article	Year
beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:8 Topics: Adrenergic beta-Antagonists; Bacterial Infections; Bacterial Translocation; Databases, Bibliographic	2009
Sclerosing encapsulating peritonitis associated with propranolol usage: a case report and review of the literature. Journal of digestive diseases, 2009, Volume: 10, Issue:4 Topics: Adrenergic beta-Antagonists; Humans; Intestinal Obstruction; Male; Middle Aged; Peritonitis; Propran	2009
A clinical view of recent advances in ascites. Journal of clinical gastroenterology, 1986, Volume: 8, Issue:1 Topics: Animals; Ascites; Ascitic Fluid; Bacterial Infections; Blood Volume; Body Water; Extracellular Space	1986

Article	Year
Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:9 Topics: Aged; Cause of Death; Databases, Factual; Denmark; Dose-Response Relationship, Drug; Female; Hepator	2016
Oral propranolol decreases intestinal permeability in patients with cirrhosis: another protective mechanism against bleeding? The American journal of gastroenterology, 2009, Volume: 104, Issue:12 Topics: Adrenergic beta-Antagonists; Bacterial Translocation; Clinical Trials as Topic; Esophageal and Gastr	2009
Beta-blockers in cirrhosis: friend and foe? Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3 Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Humans; Liver Cirrhosis; Peritonitis; P	2010
β-blockers and refractory ascites in cirrhosis: the message of a team of true scientists. Journal of hepatology, 2011, Volume: 55, Issue:4 Topics: Adrenergic beta-Antagonists; Ascites; Bacterial Infections; Cardiovascular Diseases; Female; Hepator	2011
Is hydrophobia necessary for the hepatologist prescribing nonselective beta-blockers in cirrhosis? Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:6 Topics: Adrenergic beta-Antagonists; Aged; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship,	2011
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology (Baltimore, Md.), 2003, Volume: 37, Issue:4 Topics: Antihypertensive Agents; Ascites; Bacterial Infections; Cohort Studies; Drug Therapy, Combination; F	2003
Propranolol does not affect incidence of spontaneous bacterial peritonitis in cirrhotic patients with ascites. The American journal of gastroenterology, 2003, Volume: 98, Issue:6 Topics: Adrenergic beta-Antagonists; Adult; Aged; Ascites; Bacterial Translocation; Esophageal and Gastric V	2003
Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:3 Topics: Adrenergic beta-Antagonists; Aged; Ascites; Ascitic Fluid; Bacterial Infections; Chi-Square Distribu	2006
[Prevention of variceal bleeding and measurement of hepatic vein pressure gradient]. The Korean journal of hepatology, 2006, Volume: 12, Issue:3 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Esophageal and Gastric Varices; Gastrointest	2006
Neural and hormonal influences of peritonitis on paralytic ileus. The American surgeon, 1967, Volume: 33, Issue:10 Topics: Animals; Dogs; Epinephrine; Gastrointestinal Motility; Intestinal Obstruction; Iodine; Kymography; P	1967
Sclerosing peritonitis with short-term propranolol therapy. Archives of internal medicine, 1980, Volume: 140, Issue:8 Topics: Drug Eruptions; Eye Diseases; Humans; Peritonitis; Propranolol; Sclerosis	1980
Peritoneal sclerosis in peritoneal dialysis patients. American journal of nephrology, 1984, Volume: 4, Issue:3 Topics: Adult; Humans; Male; Peritoneal Dialysis; Peritoneum; Peritonitis; Propranolol; Sclerosis	1984
Propranolol, oxprenolol, and sclerosing peritonitis. British medical journal (Clinical research ed.), 1982, Mar-20, Volume: 284, Issue:6319 Topics: Adult; Aged; Female; Humans; Intestine, Small; Male; Middle Aged; Oxprenolol; Peritoneum; Peritoniti	1982
Sclerosing peritonitis and propranolol. Chest, 1981, Volume: 79, Issue:3 Topics: Angina Pectoris; Colon; Gastrointestinal Hemorrhage; Humans; Hypertension; Male; Middle Aged; Perito	1981
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a beta-adrenoreceptor blocker. American heart journal, 1979, Volume: 98, Issue:2 Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Bronchi; Central Nervous System Diseases; Deafnes	1979
Sclerosing peritonitis and propranolol. Archives of internal medicine, 1978, Volume: 138, Issue:9 Topics: Adult; Conjunctivitis; Drug Eruptions; Humans; Male; Peritonitis; Propranolol; Sclerosis	1978
Propranolol antagonizes the anti-inflammatory effect of alcohol and improves survival of infected intoxicated rabbits. The Journal of clinical investigation, 1978, Volume: 62, Issue:3 Topics: Alcoholic Intoxication; Animals; Anti-Inflammatory Agents; Cell Adhesion; Ethanol; Granulocytes; Hum	1978
Letter: Practolol reaction. The New Zealand medical journal, 1975, Jul-23, Volume: 82, Issue:544 Topics: Female; Humans; Intestinal Obstruction; Middle Aged; Peritonitis; Practolol; Propranolol; Sclerosis	1975
Letter: Beta-blockers and fibrinous peritonitis. British medical journal, 1975, Jun-28, Volume: 2, Issue:5973 Topics: Humans; Peritonitis; Practolol; Propranolol	1975
Letter: beta-blockers and fibrinous peritonitis. British medical journal, 1975, May-31, Volume: 2, Issue:5969 Topics: Aged; Angina Pectoris; Female; Humans; Intestinal Obstruction; Peritonitis; Pleural Effusion; Practo	1975
[Hemosorption and endolymphatic therapy in the treatment of paralytic ileus in peritonitis and acute intestinal obstruction]. Vestnik khirurgii imeni I. I. Grekova, 1990, Volume: 144, Issue:3 Topics: Acute Disease; Aged; Female; Gastrointestinal Motility; Hemoperfusion; Humans; Injections, Intralymp	1990
Reflex adrenergic inhibition of colonic motility in anesthetized rat caused by nociceptive stimuli of peritoneum. An alpha 2-adrenoceptor-mediated response. Digestive diseases and sciences, 1985, Volume: 30, Issue:8 Topics: Animals; Blood Pressure; Colon; Female; Gastrointestinal Motility; Heart Rate; Isoproterenol; Male;	1985
[Use of obsidan and potassium phosphate for correction of the oxygen transport function of the blood in peritonitis]. Vestnik khirurgii imeni I. I. Grekova, 1987, Volume: 139, Issue:10 Topics: Adolescent; Adult; Aged; Child; Drug Therapy, Combination; Humans; Infusions, Intravenous; Middle Ag	1987
Inhibition of gastrointestinal transit due to surgical trauma or peritoneal irritation is reduced in capsaicin-treated rats. Gastroenterology, 1986, Volume: 91, Issue:2 Topics: Animals; Animals, Newborn; Capsaicin; Gastrointestinal Motility; Intestinal Obstruction; Intestines;	1986

propranolol and Peritonitis